Dr. Jarred Griffin

Dr. Jarred Griffin

Dr.

Principal Investigators

Education/Degrees:

2010 – 2012 Bachelor of Science (BSc), Pharmacology and Toxicology. The University of Auckland
2013 Bachelor of Science Honours (BScHons), Pharmacology. The University of Auckland
2015-2018 Doctor of Philosophy (PhD), Pharmacology. The University of Auckland

 

Academic Career:

2019 – present Postdoc, Axon Growth and Regeneration, The German Center for Neurodegenerative Diseases (DZNE).
2018 – 2019 Postdoctoral Research Fellow, Spinal Cord Injury Research Facility, The University of Auckland.

 

Awards and Honors:

2018                 Goddard Prize for best oral presentation. Australasian Winter Conference on Brain Research (AWCBR), New Zealand.

2018                 The CatWalk Trust Postdoctoral Research Fellowship, New Zealand.

2016                 Maurice and Phyllis Paykel Trust Equipment Grant, New Zealand.

2016                 Science Media Scholarship, Centre for Brain Research, New Zealand.

2016                 Velocity UoA Buissiness Innovation Challenge UniServices Special Award.

2015                 PhD Scholarship, The CatWalk Spinal Cord Injury Research Trust, New Zealand.

 

List of 10 most important publications

 

  1. Griffin JM, Bradke F (2020). Therapeutic repair for spinal cord injury: Combinatory approaches to address a multifaceted problem. EMBO Molecular Medicine. 12: e11505.
  2. Griffin JM, Fackelmeier B, Clemett CA, Fong DM, Mouravlev A, Young D, O’Carroll SJ (2020). Astrocyte-selective AAV-ADAMTS4 gene therapy combined with hindlimb rehabilitation promotes functional recovery after spinal cord injury. Experimental Neurology. 327: 113232.
  3. Griffin JM, Fackelmeier B, Fong DM, Mouravlev A, Young D, O’Carroll SJ (2019). Astrocyte-selective AAV gene therapy through the endogenous GFAP promoter results in robust transduction in the rat spinal cord following contusion injury. Nature Gene Therapy. 26: 198–210.
  4. Kim Y, Griffin JM, Mat Nor MN, Zhang J, Freestone P S, Danesh-Meyer HV, Rupenthal ID, Acosta M, Nicholson LFB, O’Carroll SJ, Green CR (2017). Tonabersat prevents inflammatory damage in the central nervous system by blocking Connexin43 hemichannels. Neurotherapeutics. 14(4):1148-1165.
  5. Kim Y, Griffin JM, Harris P, Chan C, Nicholson L, Brimble M, O’Carroll SO, Green C (2016). Characterizing the mode of action of extracellular Connexin43 channel blocking mimetic peptides in an in vitro ischemia injury model. Biochimica et Biophysica Acta (BBA) – General Subjects. 1861(2): 68-78.
  6. Griffin JM, Kho D, Graham SE, Nicholson LFB, O’Carroll SO (2016). Statins inhibit fibrillary β-Amyloid induced inflammation in a model of the human blood brain barrier. PLoS ONE. 2016. 16;11(6):e0157483.

 

Contact

Phone: +49- 228 43302 591

Email: Jarred.Griffin@dzne.de